Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Ashworth

Showing results (31-40 of 434) with videos related to

Pageof 44
Sort By:
Carcinogenesis|May 27, 2005
BRCA1 and BRCA2 as ovarian cancer susceptibility genesHeidi M Sowter, Alan Ashworth
Nature|October 18, 2013
Genomics: Comparisons across cancersAlan Ashworth, Thomas J Hudson
Nature|January 20, 2012
The DNA damage response and cancer therapyChristopher J Lord, Alan Ashworth
Breast Cancer Research and Treatment|February 9, 2011
Biomarkers of PARP inhibitor sensitivityNicholas C Turner, Alan Ashworth
Science (New York, N.Y.)|March 18, 2017
PARP inhibitors: Synthetic lethality in the clinicChristopher J Lord, Alan Ashworth
Nature Reviews. Drug Discovery|March 11, 2017
Marked for death: targeting epigenetic changes in cancerSophia Xiao Pfister, Alan Ashworth
Nature Medicine|November 9, 2013
Mechanisms of resistance to therapies targeting BRCA-mutant cancersChristopher J Lord, Alan Ashworth
Nature Genetics|July 28, 2012
AXL and acquired resistance to EGFR inhibitorsSophie Postel-Vinay, Alan Ashworth
Interactive Cardiovascular and Thoracic Surgery|June 24, 2010
Does the prophylactic administration of N-acetylcysteine prevent acute kidney injury following cardiac surgery?Alan Ashworth, Stephen T Webb
Nature Structural & Molecular Biology|June 6, 2007
RAD51, BRCA2 and DNA repair: a partial resolutionChristopher J Lord, Alan Ashworth
Pageof 44

Showing results (31-40 of 434) with videos related to

Sort By:
Pageof 44
Carcinogenesis|May 27, 2005
BRCA1 and BRCA2 as ovarian cancer susceptibility genesHeidi M Sowter, Alan Ashworth
Nature|October 18, 2013
Genomics: Comparisons across cancersAlan Ashworth, Thomas J Hudson
Nature|January 20, 2012
The DNA damage response and cancer therapyChristopher J Lord, Alan Ashworth
Breast Cancer Research and Treatment|February 9, 2011
Biomarkers of PARP inhibitor sensitivityNicholas C Turner, Alan Ashworth
Science (New York, N.Y.)|March 18, 2017
PARP inhibitors: Synthetic lethality in the clinicChristopher J Lord, Alan Ashworth
Nature Reviews. Drug Discovery|March 11, 2017
Marked for death: targeting epigenetic changes in cancerSophia Xiao Pfister, Alan Ashworth
Nature Medicine|November 9, 2013
Mechanisms of resistance to therapies targeting BRCA-mutant cancersChristopher J Lord, Alan Ashworth
Nature Genetics|July 28, 2012
AXL and acquired resistance to EGFR inhibitorsSophie Postel-Vinay, Alan Ashworth
Interactive Cardiovascular and Thoracic Surgery|June 24, 2010
Does the prophylactic administration of N-acetylcysteine prevent acute kidney injury following cardiac surgery?Alan Ashworth, Stephen T Webb
Nature Structural & Molecular Biology|June 6, 2007
RAD51, BRCA2 and DNA repair: a partial resolutionChristopher J Lord, Alan Ashworth
Pageof 44